The Market Reports

Index

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Ophthalmology Disorders Drug Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Oral
1.2.3 Injection
1.2.4 External Use
1.3 Market by Application
1.3.1 Global Ophthalmology Disorders Drug Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Juvenile Macular Degeneration (Stargardt Disease)
1.3.3 Leber Congenital Amaurosis (LCA)
1.3.4 Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy)
1.3.5 Usher Syndrome
1.3.6 Retinitis Pigmentosa (Retinitis)
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Ophthalmology Disorders Drug Market Perspective (2019-2030)
2.2 Ophthalmology Disorders Drug Growth Trends by Region
2.2.1 Global Ophthalmology Disorders Drug Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Ophthalmology Disorders Drug Historic Market Size by Region (2019-2024)
2.2.3 Ophthalmology Disorders Drug Forecasted Market Size by Region (2025-2030)
2.3 Ophthalmology Disorders Drug Market Dynamics
2.3.1 Ophthalmology Disorders Drug Industry Trends
2.3.2 Ophthalmology Disorders Drug Market Drivers
2.3.3 Ophthalmology Disorders Drug Market Challenges
2.3.4 Ophthalmology Disorders Drug Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Ophthalmology Disorders Drug Players by Revenue
3.1.1 Global Top Ophthalmology Disorders Drug Players by Revenue (2019-2024)
3.1.2 Global Ophthalmology Disorders Drug Revenue Market Share by Players (2019-2024)
3.2 Global Ophthalmology Disorders Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Ophthalmology Disorders Drug Revenue
3.4 Global Ophthalmology Disorders Drug Market Concentration Ratio
3.4.1 Global Ophthalmology Disorders Drug Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Ophthalmology Disorders Drug Revenue in 2023
3.5 Ophthalmology Disorders Drug Key Players Head office and Area Served
3.6 Key Players Ophthalmology Disorders Drug Product Solution and Service
3.7 Date of Enter into Ophthalmology Disorders Drug Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Ophthalmology Disorders Drug Breakdown Data by Type
4.1 Global Ophthalmology Disorders Drug Historic Market Size by Type (2019-2024)
4.2 Global Ophthalmology Disorders Drug Forecasted Market Size by Type (2025-2030)
5 Ophthalmology Disorders Drug Breakdown Data by Application
5.1 Global Ophthalmology Disorders Drug Historic Market Size by Application (2019-2024)
5.2 Global Ophthalmology Disorders Drug Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Ophthalmology Disorders Drug Market Size (2019-2030)
6.2 North America Ophthalmology Disorders Drug Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Ophthalmology Disorders Drug Market Size by Country (2019-2024)
6.4 North America Ophthalmology Disorders Drug Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Ophthalmology Disorders Drug Market Size (2019-2030)
7.2 Europe Ophthalmology Disorders Drug Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Ophthalmology Disorders Drug Market Size by Country (2019-2024)
7.4 Europe Ophthalmology Disorders Drug Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Ophthalmology Disorders Drug Market Size (2019-2030)
8.2 Asia-Pacific Ophthalmology Disorders Drug Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Ophthalmology Disorders Drug Market Size by Region (2019-2024)
8.4 Asia-Pacific Ophthalmology Disorders Drug Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Ophthalmology Disorders Drug Market Size (2019-2030)
9.2 Latin America Ophthalmology Disorders Drug Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Ophthalmology Disorders Drug Market Size by Country (2019-2024)
9.4 Latin America Ophthalmology Disorders Drug Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Ophthalmology Disorders Drug Market Size (2019-2030)
10.2 Middle East & Africa Ophthalmology Disorders Drug Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Ophthalmology Disorders Drug Market Size by Country (2019-2024)
10.4 Middle East & Africa Ophthalmology Disorders Drug Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Sanofi
11.1.1 Sanofi Company Detail
11.1.2 Sanofi Business Overview
11.1.3 Sanofi Ophthalmology Disorders Drug Introduction
11.1.4 Sanofi Revenue in Ophthalmology Disorders Drug Business (2019-2024)
11.1.5 Sanofi Recent Development
11.2 Bayer
11.2.1 Bayer Company Detail
11.2.2 Bayer Business Overview
11.2.3 Bayer Ophthalmology Disorders Drug Introduction
11.2.4 Bayer Revenue in Ophthalmology Disorders Drug Business (2019-2024)
11.2.5 Bayer Recent Development
11.3 Bausch + Lomb
11.3.1 Bausch + Lomb Company Detail
11.3.2 Bausch + Lomb Business Overview
11.3.3 Bausch + Lomb Ophthalmology Disorders Drug Introduction
11.3.4 Bausch + Lomb Revenue in Ophthalmology Disorders Drug Business (2019-2024)
11.3.5 Bausch + Lomb Recent Development
11.4 Novartis
11.4.1 Novartis Company Detail
11.4.2 Novartis Business Overview
11.4.3 Novartis Ophthalmology Disorders Drug Introduction
11.4.4 Novartis Revenue in Ophthalmology Disorders Drug Business (2019-2024)
11.4.5 Novartis Recent Development
11.5 Usher Syndrome
11.5.1 Usher Syndrome Company Detail
11.5.2 Usher Syndrome Business Overview
11.5.3 Usher Syndrome Ophthalmology Disorders Drug Introduction
11.5.4 Usher Syndrome Revenue in Ophthalmology Disorders Drug Business (2019-2024)
11.5.5 Usher Syndrome Recent Development
11.6 Takeda Pharmaceutical
11.6.1 Takeda Pharmaceutical Company Detail
11.6.2 Takeda Pharmaceutical Business Overview
11.6.3 Takeda Pharmaceutical Ophthalmology Disorders Drug Introduction
11.6.4 Takeda Pharmaceutical Revenue in Ophthalmology Disorders Drug Business (2019-2024)
11.6.5 Takeda Pharmaceutical Recent Development
11.7 Roche
11.7.1 Roche Company Detail
11.7.2 Roche Business Overview
11.7.3 Roche Ophthalmology Disorders Drug Introduction
11.7.4 Roche Revenue in Ophthalmology Disorders Drug Business (2019-2024)
11.7.5 Roche Recent Development
11.8 Pfizer
11.8.1 Pfizer Company Detail
11.8.2 Pfizer Business Overview
11.8.3 Pfizer Ophthalmology Disorders Drug Introduction
11.8.4 Pfizer Revenue in Ophthalmology Disorders Drug Business (2019-2024)
11.8.5 Pfizer Recent Development
11.9 Allergan
11.9.1 Allergan Company Detail
11.9.2 Allergan Business Overview
11.9.3 Allergan Ophthalmology Disorders Drug Introduction
11.9.4 Allergan Revenue in Ophthalmology Disorders Drug Business (2019-2024)
11.9.5 Allergan Recent Development
11.10 Gilead Sciences
11.10.1 Gilead Sciences Company Detail
11.10.2 Gilead Sciences Business Overview
11.10.3 Gilead Sciences Ophthalmology Disorders Drug Introduction
11.10.4 Gilead Sciences Revenue in Ophthalmology Disorders Drug Business (2019-2024)
11.10.5 Gilead Sciences Recent Development
11.11 Kubota Pharmaceutical
11.11.1 Kubota Pharmaceutical Company Detail
11.11.2 Kubota Pharmaceutical Business Overview
11.11.3 Kubota Pharmaceutical Ophthalmology Disorders Drug Introduction
11.11.4 Kubota Pharmaceutical Revenue in Ophthalmology Disorders Drug Business (2019-2024)
11.11.5 Kubota Pharmaceutical Recent Development
11.12 Alkeus Pharmaceuticals
11.12.1 Alkeus Pharmaceuticals Company Detail
11.12.2 Alkeus Pharmaceuticals Business Overview
11.12.3 Alkeus Pharmaceuticals Ophthalmology Disorders Drug Introduction
11.12.4 Alkeus Pharmaceuticals Revenue in Ophthalmology Disorders Drug Business (2019-2024)
11.12.5 Alkeus Pharmaceuticals Recent Development
11.13 Astellas Pharma
11.13.1 Astellas Pharma Company Detail
11.13.2 Astellas Pharma Business Overview
11.13.3 Astellas Pharma Ophthalmology Disorders Drug Introduction
11.13.4 Astellas Pharma Revenue in Ophthalmology Disorders Drug Business (2019-2024)
11.13.5 Astellas Pharma Recent Development
11.14 Ferrer Corporate
11.14.1 Ferrer Corporate Company Detail
11.14.2 Ferrer Corporate Business Overview
11.14.3 Ferrer Corporate Ophthalmology Disorders Drug Introduction
11.14.4 Ferrer Corporate Revenue in Ophthalmology Disorders Drug Business (2019-2024)
11.14.5 Ferrer Corporate Recent Development
11.15 Amgen Inc
11.15.1 Amgen Inc Company Detail
11.15.2 Amgen Inc Business Overview
11.15.3 Amgen Inc Ophthalmology Disorders Drug Introduction
11.15.4 Amgen Inc Revenue in Ophthalmology Disorders Drug Business (2019-2024)
11.15.5 Amgen Inc Recent Development
11.16 Editas Medicine Inc
11.16.1 Editas Medicine Inc Company Detail
11.16.2 Editas Medicine Inc Business Overview
11.16.3 Editas Medicine Inc Ophthalmology Disorders Drug Introduction
11.16.4 Editas Medicine Inc Revenue in Ophthalmology Disorders Drug Business (2019-2024)
11.16.5 Editas Medicine Inc Recent Development
11.17 ProQR Therapeutics NV
11.17.1 ProQR Therapeutics NV Company Detail
11.17.2 ProQR Therapeutics NV Business Overview
11.17.3 ProQR Therapeutics NV Ophthalmology Disorders Drug Introduction
11.17.4 ProQR Therapeutics NV Revenue in Ophthalmology Disorders Drug Business (2019-2024)
11.17.5 ProQR Therapeutics NV Recent Development
11.18 ReNeuron
11.18.1 ReNeuron Company Detail
11.18.2 ReNeuron Business Overview
11.18.3 ReNeuron Ophthalmology Disorders Drug Introduction
11.18.4 ReNeuron Revenue in Ophthalmology Disorders Drug Business (2019-2024)
11.18.5 ReNeuron Recent Development
11.19 Amarantus BioScience
11.19.1 Amarantus BioScience Company Detail
11.19.2 Amarantus BioScience Business Overview
11.19.3 Amarantus BioScience Ophthalmology Disorders Drug Introduction
11.19.4 Amarantus BioScience Revenue in Ophthalmology Disorders Drug Business (2019-2024)
11.19.5 Amarantus BioScience Recent Development
11.20 Ocugen
11.20.1 Ocugen Company Detail
11.20.2 Ocugen Business Overview
11.20.3 Ocugen Ophthalmology Disorders Drug Introduction
11.20.4 Ocugen Revenue in Ophthalmology Disorders Drug Business (2019-2024)
11.20.5 Ocugen Recent Development
11.21 ReGenX Biosciences
11.21.1 ReGenX Biosciences Company Detail
11.21.2 ReGenX Biosciences Business Overview
11.21.3 ReGenX Biosciences Ophthalmology Disorders Drug Introduction
11.21.4 ReGenX Biosciences Revenue in Ophthalmology Disorders Drug Business (2019-2024)
11.21.5 ReGenX Biosciences Recent Development
11.22 Sucampo Pharmaceuticals
11.22.1 Sucampo Pharmaceuticals Company Detail
11.22.2 Sucampo Pharmaceuticals Business Overview
11.22.3 Sucampo Pharmaceuticals Ophthalmology Disorders Drug Introduction
11.22.4 Sucampo Pharmaceuticals Revenue in Ophthalmology Disorders Drug Business (2019-2024)
11.22.5 Sucampo Pharmaceuticals Recent Development
11.23 Orphagen Pharmaceuticals
11.23.1 Orphagen Pharmaceuticals Company Detail
11.23.2 Orphagen Pharmaceuticals Business Overview
11.23.3 Orphagen Pharmaceuticals Ophthalmology Disorders Drug Introduction
11.23.4 Orphagen Pharmaceuticals Revenue in Ophthalmology Disorders Drug Business (2019-2024)
11.23.5 Orphagen Pharmaceuticals Recent Development
11.24 Okuvision
11.24.1 Okuvision Company Detail
11.24.2 Okuvision Business Overview
11.24.3 Okuvision Ophthalmology Disorders Drug Introduction
11.24.4 Okuvision Revenue in Ophthalmology Disorders Drug Business (2019-2024)
11.24.5 Okuvision Recent Development
11.25 Second Sight Medical
11.25.1 Second Sight Medical Company Detail
11.25.2 Second Sight Medical Business Overview
11.25.3 Second Sight Medical Ophthalmology Disorders Drug Introduction
11.25.4 Second Sight Medical Revenue in Ophthalmology Disorders Drug Business (2019-2024)
11.25.5 Second Sight Medical Recent Development
11.26 Acucela
11.26.1 Acucela Company Detail
11.26.2 Acucela Business Overview
11.26.3 Acucela Ophthalmology Disorders Drug Introduction
11.26.4 Acucela Revenue in Ophthalmology Disorders Drug Business (2019-2024)
11.26.5 Acucela Recent Development
11.27 Stealth BioTherapeutics
11.27.1 Stealth BioTherapeutics Company Detail
11.27.2 Stealth BioTherapeutics Business Overview
11.27.3 Stealth BioTherapeutics Ophthalmology Disorders Drug Introduction
11.27.4 Stealth BioTherapeutics Revenue in Ophthalmology Disorders Drug Business (2019-2024)
11.27.5 Stealth BioTherapeutics Recent Development
11.28 Sun Pharma Advanced Research Company
11.28.1 Sun Pharma Advanced Research Company Company Detail
11.28.2 Sun Pharma Advanced Research Company Business Overview
11.28.3 Sun Pharma Advanced Research Company Ophthalmology Disorders Drug Introduction
11.28.4 Sun Pharma Advanced Research Company Revenue in Ophthalmology Disorders Drug Business (2019-2024)
11.28.5 Sun Pharma Advanced Research Company Recent Development
11.29 AmpliPhi Biosciences
11.29.1 AmpliPhi Biosciences Company Detail
11.29.2 AmpliPhi Biosciences Business Overview
11.29.3 AmpliPhi Biosciences Ophthalmology Disorders Drug Introduction
11.29.4 AmpliPhi Biosciences Revenue in Ophthalmology Disorders Drug Business (2019-2024)
11.29.5 AmpliPhi Biosciences Recent Development
11.30 Applied Genetic Technologies
11.30.1 Applied Genetic Technologies Company Detail
11.30.2 Applied Genetic Technologies Business Overview
11.30.3 Applied Genetic Technologies Ophthalmology Disorders Drug Introduction
11.30.4 Applied Genetic Technologies Revenue in Ophthalmology Disorders Drug Business (2019-2024)
11.30.5 Applied Genetic Technologies Recent Development
11.31 Asklepios BioPharmaceutical
11.31.1 Asklepios BioPharmaceutical Company Detail
11.31.2 Asklepios BioPharmaceutical Business Overview
11.31.3 Asklepios BioPharmaceutical Ophthalmology Disorders Drug Introduction
11.31.4 Asklepios BioPharmaceutical Revenue in Ophthalmology Disorders Drug Business (2019-2024)
11.31.5 Asklepios BioPharmaceutical Recent Development
11.32 Biovista
11.32.1 Biovista Company Detail
11.32.2 Biovista Business Overview
11.32.3 Biovista Ophthalmology Disorders Drug Introduction
11.32.4 Biovista Revenue in Ophthalmology Disorders Drug Business (2019-2024)
11.32.5 Biovista Recent Development
11.33 Spark Therapeutics
11.33.1 Spark Therapeutics Company Detail
11.33.2 Spark Therapeutics Business Overview
11.33.3 Spark Therapeutics Ophthalmology Disorders Drug Introduction
11.33.4 Spark Therapeutics Revenue in Ophthalmology Disorders Drug Business (2019-2024)
11.33.5 Spark Therapeutics Recent Development
11.34 Caladrius Biosciences
11.34.1 Caladrius Biosciences Company Detail
11.34.2 Caladrius Biosciences Business Overview
11.34.3 Caladrius Biosciences Ophthalmology Disorders Drug Introduction
11.34.4 Caladrius Biosciences Revenue in Ophthalmology Disorders Drug Business (2019-2024)
11.34.5 Caladrius Biosciences Recent Development
11.35 Dompe Farmaceutici
11.35.1 Dompe Farmaceutici Company Detail
11.35.2 Dompe Farmaceutici Business Overview
11.35.3 Dompe Farmaceutici Ophthalmology Disorders Drug Introduction
11.35.4 Dompe Farmaceutici Revenue in Ophthalmology Disorders Drug Business (2019-2024)
11.35.5 Dompe Farmaceutici Recent Development
11.36 Dormant Projects
11.36.1 Dormant Projects Company Detail
11.36.2 Dormant Projects Business Overview
11.36.3 Dormant Projects Ophthalmology Disorders Drug Introduction
11.36.4 Dormant Projects Revenue in Ophthalmology Disorders Drug Business (2019-2024)
11.36.5 Dormant Projects Recent Development
11.37 Grupo Ferrer Internacional
11.37.1 Grupo Ferrer Internacional Company Detail
11.37.2 Grupo Ferrer Internacional Business Overview
11.37.3 Grupo Ferrer Internacional Ophthalmology Disorders Drug Introduction
11.37.4 Grupo Ferrer Internacional Revenue in Ophthalmology Disorders Drug Business (2019-2024)
11.37.5 Grupo Ferrer Internacional Recent Development
11.38 ID Pharma
11.38.1 ID Pharma Company Detail
11.38.2 ID Pharma Business Overview
11.38.3 ID Pharma Ophthalmology Disorders Drug Introduction
11.38.4 ID Pharma Revenue in Ophthalmology Disorders Drug Business (2019-2024)
11.38.5 ID Pharma Recent Development
11.39 InFlectis BioScience
11.39.1 InFlectis BioScience Company Detail
11.39.2 InFlectis BioScience Business Overview
11.39.3 InFlectis BioScience Ophthalmology Disorders Drug Introduction
11.39.4 InFlectis BioScience Revenue in Ophthalmology Disorders Drug Business (2019-2024)
11.39.5 InFlectis BioScience Recent Development
11.40 Ionis Pharmaceuticals
11.40.1 Ionis Pharmaceuticals Company Detail
11.40.2 Ionis Pharmaceuticals Business Overview
11.40.3 Ionis Pharmaceuticals Ophthalmology Disorders Drug Introduction
11.40.4 Ionis Pharmaceuticals Revenue in Ophthalmology Disorders Drug Business (2019-2024)
11.40.5 Ionis Pharmaceuticals Recent Development
11.41 Ixchel Pharma
11.42 Khondrion
11.43 Mimetogen Pharmaceuticals
11.44 Mitotech
11.45 M's Science
11.46 Nanovector
11.47 SanBio
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details